Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacillus Anthracis (Anthrax) Infection

Interventions

BIOLOGICAL: BioThrax
BIOLOGICAL: AV7909 Formulation 1
BIOLOGICAL: AV7909 Formulation 2
BIOLOGICAL: AV7909 Formulation 3
BIOLOGICAL: AV7909 Formulation 4
DRUG: Control

Sponsor

Emergent BioSolutions

Collaborators

[object Object]
[object Object]